142 related articles for article (PubMed ID: 12499223)
1. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Gunderson BW; Ibrahim KH; Peloquin CA; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 2003 Jan; 47(1):398-9. PubMed ID: 12499223
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Allen GP; Bierman BC
Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria].
Eraç B; Taşli H; Ermertcan S; Cilli F; Limoncu MH
Mikrobiyol Bul; 2009 Jan; 43(1):45-51. PubMed ID: 19334379
[TBL] [Abstract][Full Text] [Related]
8. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
9. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
[TBL] [Abstract][Full Text] [Related]
11. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
Munckhof WJ; Giles C; Turnidge JD
J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
[TBL] [Abstract][Full Text] [Related]
12. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
Ho PL; Ng TK; Yung RW; Que TL; Yip EK; Tse CW; Yuen KY
J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
[No Abstract] [Full Text] [Related]
13. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
14. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
[TBL] [Abstract][Full Text] [Related]
16. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Sweeney MT; Zurenko GE
Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
Livermore DM; Warner M; Mushtaq S; North S; Woodford N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
[TBL] [Abstract][Full Text] [Related]
19. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.
Ba BB; Arpin C; Bikie Bi Nso B; Dubois V; Saux MC; Quentin C
Antimicrob Agents Chemother; 2010 Apr; 54(4):1443-52. PubMed ID: 20100878
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]